RT Journal Article
SR Electronic
T1 Detection of cognitive decline using a single-channel EEG system with an interactive assessment tool
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.13.20171876
DO 10.1101/2020.08.13.20171876
A1 Molcho, Lior
A1 Maimon, Neta B.
A1 Pressburger, Narkiss
A1 Regev-Plotnik, Noa
A1 Rabinowicz, Sarit
A1 Intrator, Nathan
A1 Sasson, Ady
YR 2020
UL http://medrxiv.org/content/early/2020/08/15/2020.08.13.20171876.abstract
AB Background Cognitive decline remains highly underdiagnosed in the community despite extensive efforts to find novel biomarkers to detect it. Finding objective screening tools for cognitive decline may improve early diagnosis of Alzheimer’s disease (AD) in the community. EEG biomarkers based on machine learning (ML) may offer a noninvasive low-coast approach for identifying cognitive decline with clinically useful accuracy. However, most of the studies use multi-electrode systems which are not vastly accessible. This study aims to evaluate the ability to extract cognitive decline biomarkers using a wearable single-channel EEG system with a short interactive cognitive assessment tool.Methods Seniors in different clinical stages of cognitive decline (healthy to mild dementia, n=60) and young healthy participants (n=22) performed a cognitive assessment which included auditory detection and resting state tasks, while being recorded with a single-channel EEG (Aurora by Neurosteer®). Seniors’ MMSE scores were obtained by clinicians and used in allocating the groups (Healthy: MMSE≥28; MCI-R: 28>MMSE≥24; and MD: MMSE<24). Data analysis included standard frequency bands as well as three novel biomarkers, A0, ST4 and VC9, previously extracted from a different dataset to minimize overfitting risks.Results Correlation between MMSE scores and reaction times was significant, validating the cognitive assessment tool. Individual MMSE scores correlated significantly with two of the EEG biomarkers: A0 and ST4. Furthermore, A0 and ST4 showed significant separation between groups of seniors with high vs. low MMSE scores, as well as the healthy young group. ST4 separated between the healthy groups (young and seniors) and the low MMSE (MD) group. Conversely, A0 differentiated between the healthy young group and all three groups of seniors. In the healthy young group, activity of Theta band and VC9 biomarker significantly increased with higher cognitive load, with both separating between the high cognitive load task and resting state. Furthermore, VC9 showed a finer separation between high and low cognitive load levels within the cognitive task. This was not shown in the senior groups, suggesting VC9 may be indicative to cognitive decline in the senior population.Conclusions These results introduce novel biomarkers which potentially detect cognitive decline, obtained by a wearable single-channel EEG with a short interactive cognitive assessment. Such objective screening tools can be used on a large scale to detect cognitive decline and potentially allow early diagnosis of AD in every clinic.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04386902Funding StatementNo external funding was received for this study. The equipment was provided by Neurosteer Inc. as part of the trial.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was granted by the Ethics Committee (EC) of Dorot Geriatric Medical Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to restrictions (containing information that could compromise the privacy of research participants).